Dr. Christian Wolf is a co-founder and managing partner of Lycalis sprl, a Belgian limited company established in 2009.
Over the past 20 years, Dr. Wolf held project and line management positions at global pharmaceutical companies. In these roles, he led numerous early and late-stage clinical development programmes in CNS indications to decision points. He has been a principal investigator or member of steering committees for many clinical studies in the field of neurology covering a range of technological platforms including small molecules, therapeutic proteins, antibodies, and biosimilars.
Dr. Wolf's expertise comprises a range of CNS indications with most recent exposure to multiple sclerosis, epilepsy, and cognitive disorders. Additional activities in ischemic stroke, bipolar disorders, and movement disorders complement his profile as a CNS "all-rounder".
Dr. Wolf managed MDs, scientists, and other development professionals in Europe and the US. Responsibilities included activities for blockbuster drugs such as Keppra® or Betaferon®. His track record includes also interaction with major regulatory agencies (EMA, FDA, BfArM, MHRA) and collaborative projects with North American and Japanese corporations.
As a consultant, Dr. Wolf has been retained by European and non-European companies as well as by authorities such as the European Commission's DG for Research and Innovation. Clients included top-5, mid-sized, start-up, and VC entities.
The scope of services comprised strategic consultancy and interim management in clinical development for small and complex molecules in neurological disorders.
